OHSU

Joshi J. Alumkal, M.D.

Head Shot of Joshi Alumkal

Associate Professor of Medicine

Email: 
click here
Office: 
503 494-6594

Lab Page: Click here


Background

Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible changes in gene expression in cancer. His laboratory studies key chromatin modifying enzymes in cancer with an eye towards: 1) elucidating their function and role in transformation and disease progression and 2) targeting them with pharmacological agents in order to improve our ability to prevent and treat men with prostate cancer. Finally, his laboratory also focuses on the identification of biomarkers associated with prostate cancer development or aggressiveness.


Selected Publications

"Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation," PLoS ONE (Vol: 8, Issue: 5, ) - 2013

"Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study," Prostate (Vol: 73, Issue: 13, Page 1371-1377) - 2013

"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i/ii study," Annals of Oncology (Vol: 24, Issue: 7, Page 1813-1821) - 2013

"Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone," Clinical Cancer Research (Vol: 19, Issue: 1, Page 215-224) - 2013

"Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?," Oncology (Williston Park, N.Y.) (Vol: 27, Issue: 7, Page 628, 630, 637-638) - 2013

 

Back to faculty list

OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


Contact

  Email Joshi Alumkal

503 494-6594

Memberships & Associations

American College of Physicians

American Society of Clinical Oncology

American Society of Hematology

American Association for Cancer Research

Southwest Oncology Group

Radiation Therapy Oncology Group